Immucell (ICCC) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$139748.0.
- Immucell's Net Income towards Common Stockholders rose 8008.41% to -$139748.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 16097.25%. This contributed to the annual value of -$2.2 million for FY2024, which is 6265.32% up from last year.
- As of Q3 2025, Immucell's Net Income towards Common Stockholders stood at -$139748.0, which was up 8008.41% from $501880.0 recorded in Q2 2025.
- In the past 5 years, Immucell's Net Income towards Common Stockholders registered a high of $1.4 million during Q1 2025, and its lowest value of -$2.3 million during Q1 2023.
- Moreover, its 5-year median value for Net Income towards Common Stockholders was -$441303.0 (2021), whereas its average is -$460301.4.
- Per our database at Business Quant, Immucell's Net Income towards Common Stockholders crashed by 234979.9% in 2022 and then surged by 43046.1% in 2025.
- Over the past 5 years, Immucell's Net Income towards Common Stockholders (Quarter) stood at $74134.0 in 2021, then tumbled by 2349.8% to -$1.7 million in 2022, then soared by 31.66% to -$1.1 million in 2023, then surged by 145.14% to $514555.0 in 2024, then crashed by 127.16% to -$139748.0 in 2025.
- Its last three reported values are -$139748.0 in Q3 2025, $501880.0 for Q2 2025, and $1.4 million during Q1 2025.